Last reviewed · How we verify
EGT0001474
At a glance
| Generic name | EGT0001474 |
|---|---|
| Also known as | Human SGLT2 inhibitor |
| Sponsor | Theracos |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EGT0001474 CI brief — competitive landscape report
- EGT0001474 updates RSS · CI watch RSS
- Theracos portfolio CI